Lucira Health

Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company was founded by Debkishore Mitra, John Robert Waldeisen and Benjamin Ross in 2013 and is headquartered in Emeryville, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.

Combination Test Also Secures Point-Of-Care Authorization in Australia Combination Test Also Secures Point-Of-Care Authorization in Australia

Lucira Health Announces U.S. Launch of First & Only At-Home Combination COVID-19 & Flu Test Amidst Sale Process

Lucira Health (NASDAQ: LHDX ) stock is falling on Friday after the company's shares have seen extreme volatility throughout the week. That includes a massive rally earlier this week that saw the company's shares gain as much as 871% since its closing price on Friday.

Why Is Lucira Health (LHDX) Stock Down 14% Today?

Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test. The over-the-counter (OTC) 30-minute at-home rapid test can detect influenza A and B and the SARS-CoV-2 virus using nasal swabs.

Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11

Cardio Diagnostics Holdings In

Helbiz

Using liquidity and volume to make money with penny stocks The post Penny Stocks: The Importance of Liquidity and Volume appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks: The Importance of Liquidity and Volume

Nuburu Inc

Eos Energy Enterprises

Faraday Future Intelligent Electric

Protalix Biotherapeutics

Troika Media Group

GeneDx Holdings Corp

Cheap penny stocks to watch before next week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 7 Under $5 To Watch Before Next Week

Lucira Health Inc shares have added more than 300% after it announced on Friday that the US Food and Drug Administration (FDA) has granted emergency use authorization for its combination COVID-19 and flu test for use at home and in non-laboratory settings, just days after the company filed for Chapter 11 bankruptcy. The company said the molecular test delivers results in 30 minutes or less from a shallow nasal swab and demonstrated similar performance for COVID-19 and Influenza A and B compared to highly sensitive lab-based PCR tests in clinical trials.

Lucira Health shares rise more than 300% on FDA authorization of at-home combination COVID-19 and flu test

Lucira Health (NASDAQ: LHDX ) stock is rocketing higher on Monday thanks to an update from the FDA. The big news here is Lucira Health getting FDA approval for its at-home Covid-19 and flu combination tests.

Why Is Lucira Health (LHDX) Stock Up 237% Today?

Lucira Health Inc. LHDX, +13.45% shares more than doubled in the extended session Friday after the Food and Drug Administration authorized use of its at-home test that can detect both the flu and the virus that causes COVID-19. Shares of Lucira soared more than 150% after hours, following a regular session gain of 13.5% to close at 14 cents.

Lucira stock more than doubles after hours on FDA OK for COVID-19, flu test

Lucira Health (NASDAQ: LHDX ) stock is taking a beating on Thursday after the company filed for Chapter 11 bankruptcy protection. To go along with that filing, Lucira Health says it intends to sell its business during the bankruptcy process.

Why Is Lucira Health (LHDX) Stock Down 34% Today?

No debtor-in-possession financing required as the Company intends to fund operations and the sale process with available cash on hand. No debtor-in-possession financing required as the Company intends to fund operations and the sale process with available cash on hand.

Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

Ameriprise Financial

AppHarvest

Lucid Group

Life Time Group Holdings

AppHarvest (APPH), Lucira Health (LHDX), Lucid Group (LCID), Life Time Group (LTH) & Ameriprise Financial (AMP) not only have made the most of the January rally but also are poised to gain further this year.

5 Big Winners as Wall Street Wraps Up Strong January Gains

EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, today announced the Canadian launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the price of the test, excluding prescription costs. Lucira Connect is currently offered in British Columbia, Ontario and Alberta with plans to expand.

Lucira Health Launches Lucira Connect, a Free Test-to-Treat Telehealth Service for Covid-19 or Flu in Canada

One of the biggest upside movers in today's upside-down market is medical technology company Lucira Health (NASDAQ: LHDX ). This little-known maker of PCR tests for various infectious diseases is on a tear, with LHDX stock up more than 400% as of early afternoon trading.

Why Lucira Health (LHDX) Stock Up 400% Today?

With 99% accuracy and within 30 minutes, institutions will simultaneously and accurately test residents, health workers and visitors for COVID-19 and Flu A/B With 99% accuracy and within 30 minutes, institutions will simultaneously and accurately test residents, health workers and visitors for COVID-19 and Flu A/B

Lucira and Loch Lomond Villa Announce Clinical Study to Tackle Tripledemic With First and Only Combination COVID-19 and Flu OTC Molecular Self-Test

PCR-Quality Accuracy with Results in 30 Minutes or Less, Just in Time for Flu Season PCR-Quality Accuracy with Results in 30 Minutes or Less, Just in Time for Flu Season

Lucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-Care

EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX) today announced the launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the $29 price of the test, excluding prescription costs.

Lucira Health Announces National Launch of Lucira Connect Test-to-Treat Service

Lucira Health, Inc. (NASDAQ:LHDX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Greg Chodaczek – Gilmartin Group Erik Engelson – President and Chief Executive Officer Dan George – Chief Financial Officer Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Lucira Health Third Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.

Lucira Health, Inc. (LHDX) Q3 2022 Earnings Call Transcript

EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates.

Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates

EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Lucira Health to Announce Third Quarter 2022 Financial Results

Study Reveals Lucira's Testing Assays Offer a 98% Accuracy Rate in Detecting Both Sexually Transmitted Infections Study Reveals Lucira's Testing Assays Offer a 98% Accuracy Rate in Detecting Both Sexually Transmitted Infections

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays

EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, and a digital health platform that will connect patients with providers, today announced that the company will participate in the LifeSci Partners HealthTech Symposium on September 21st, 2022, at 10:30am ET. A live and archived webcast of the event can be accessed through the Events and Presentations page of the Lucira website.

Lucira Health to Participate in LifeSci Partners HealthTech Symposium

EMERYVILLE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31st, 2022.

Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Lucira Health, Inc. (NASDAQ:LHDX ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Louisa Smith – Investor Relations Erik Engelson – President and Chief Executive Officer Dan George – Chief Financial Officer and Treasurer Conference Call Participants Griffin Soriano – William Blair John Kim – Bank of America Rahul Rakhit – LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to Lucira Health Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Lucira Health, Inc. (LHDX) CEO Erik Engelson on Q2 2022 Results - Earnings Call Transcript

EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates.

Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates

EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today announced that Health Canada has granted Authorization under Interim Order for the emergency use and commercialization of the first and only at-home test for COVID & Flu. The Lucira COVID-19 & Flu Test is a 99% accurate rapid molecular test that delivers results in 30 minutes or less from one shallow nasal swab.

News for Lucira Health Stock (LHDX)